News

Targeted Oncology17h
INAVO120: Inavolisib Triplet Extends OS in PIK3CA-Mutant Breast Cancer
INAVO120 trial shows inavolisib, palbociclib, and fulvestrant significantly improved overall survival in PIK3CA-mutant ...
Precision Medicine Online17h
Roche's Itovebi Regimen Extends Overall Survival, Delays Chemotherapy in Updated Trial Results
The latest readout from INAVO120 marks the first time a PI3K-inhibiting targeted treatment has shown an overall survival advantage.